The latest episode of Inside U Miami Medicine delves into the complex and often misunderstood world of migraine, a disabling neurological disorder that affects 40 million people worldwide.
Despite its prevalence, this common disease still carries deep stigma.
Teshamay Monteith, M.D., chief of the Headache Division at the University of Miami Miller School of Medicine, highlights groundbreaking research and new treatment options aimed at reshaping the way we think about and treat migraines. This episode begins by investigating calcitonin gene-related peptide (CGRP), an important neuropeptide that has been identified as a cause of migraine attacks.
“When a migraine attack occurs, a number of peptides are released,” says Dr. Monteith, who is also a professor of clinical neurology at the Miller School. “And we clearly see a relationship between CGRP and migraines.”
Dr. Monteith also shares pharmaceutical innovations, highlighting the potential of non-invasive electrical neuromodulation devices designed to prevent migraines. These devices use electrical impulses to suppress or enhance neural activity, offering new therapeutic avenues.
This compelling episode delves into the science, stigma, and future of migraine treatment, offering both hope and practical insight for those affected by this widespread disease.
